Peritoneal Cancer

In conclusion, this study indicates that tumor-infiltrating ADSCs promote glycolysis and anoikis resistance in CRC cells and ultimately facilitate peritoneal metastasis via the TGF-β1/SMAD3/ANGPTL4 axis. The dual-targeting of TGF-β signaling and ANGPTL4 may be a feasible therapeutic strategy for CRC peritoneal metastasis.

Our data suggest that molecular classification does not seem useful to tailor the need of nodal dissection in apparent early-stage endometrial cancer. p53 abnormality predicts the risk of having advanced disease at presentation. Further external validation is needed.

P1/2, N=14, Terminated, Avenge Bio, Inc | Trial completion date: Aug 2026 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Apr 2024; Sponsor Decision to close study

P3, N=448, Recruiting, Mural Oncology, Inc | Active, not recruiting --> Recruiting | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2026

When a retroperitoneal tumour is not clinically suspected, histological consideration of a liposarcoma diagnosis may be overlooked. Implementation of ancillary immunohistochemical and cytogenetic testing can ultimately lead to a definitive diagnosis in this potentially misleading anatomical location.

P2, N=100, Recruiting, Vall d'Hebron Institute of Oncology

P1, N=43, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting | N=21 --> 43

Inhibiting the IGF-1 receptor (IGF1R) initially increased tumor omental adhesion but decreased growth of established preadipocyte-induced subcutaneous tumors as well as established intraperitoneal tumors. Together, this study shows that omental preadipocytes support ovarian cancer progression, which has implications for targeting metastasis.

P1/2, N=47, Terminated, Sumitomo Pharma America, Inc. | Phase classification: P1b/2 --> P1/2 | Completed --> Terminated; Sponsor's decision to terminate development of the program.

P1, N=120, Recruiting, Volastra Therapeutics, Inc. | Not yet recruiting --> Recruiting | Phase classification: P1b --> P1

P1/2, N=14, Terminated, Enlivex Therapeutics RDO Ltd. | N=72 --> 14 | Trial completion date: Dec 2024 --> Apr 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Apr 2024; Sponsor decision

P2/3, N=600, Recruiting, Sutro Biopharma, Inc. | Phase classification: P2 --> P2/3 | N=140 --> 600

P=N/A, N=48, Recruiting, National Taiwan University Hospital | Phase classification: P2 --> P=N/A

P3, N=186, Recruiting, Genelux Corporation | Trial primary completion date: Aug 2024 --> Aug 2025

P2, N=5, Active, not recruiting, Jonsson Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 5 | Trial primary completion date: Mar 2024 --> Dec 2023

In patients with CRC PM, different KRAS mutation subgroups can be determined according to specific codon substitution, with some mutations (KRASMUT1) that could have a similar prognosis to wild-type patients. These findings should be further investigated in larger series.

P1, N=38, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026

P1, N=46, Terminated, University of Pennsylvania | N=18 --> 46 | Trial completion date: Oct 2038 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Oct 2038 --> Mar 2024; This study was halted prematurely due to recruitment barriers

P=N/A, N=255, Completed, University of Minnesota | Recruiting --> Completed | Trial completion date: Jun 2026 --> Apr 2024 | Trial primary completion date: Jun 2025 --> Apr 2024

P=N/A, N=30, Completed, Royal Surrey County Hospital NHS Foundation Trust | Recruiting --> Completed

P1, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=22, Recruiting, University of Washington | Trial primary completion date: Apr 2024 --> Dec 2024 | Trial completion date: Apr 2025 --> Dec 2025

P1/2, N=10, Terminated, Pfizer | Active, not recruiting --> Terminated; A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.

P1, N=49, Active, not recruiting, Oncoinvent AS | Recruiting --> Active, not recruiting

P1/2, N=67, Active, not recruiting, Oncoinvent AS | Recruiting --> Active, not recruiting

P1/2, N=75, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

P2, N=11, Terminated, Laval University | N=30 --> 11 | Trial completion date: Dec 2024 --> Mar 2024 | Recruiting --> Terminated; Recruitment lower than expected and negative results.

P1, N=21, Suspended, M.D. Anderson Cancer Center | N=36 --> 21 | Recruiting --> Suspended

P2, N=460, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting

P1, N=33, Not yet recruiting, Masonic Cancer Center, University of Minnesota

P1/2, N=141, Active, not recruiting, 23andMe, Inc. | Recruiting --> Active, not recruiting

Robotic interval debulking surgery appears safe and feasible for experienced robotic surgeons in patients with a pelvic mass ≤8 cm. A randomized controlled trial (MIRRORS-RCT) will determine whether MIRRORS protocol has non-inferior survival (overall and progression-free) compared with open interval debulking surgery.

P=N/A, N=22, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

P=N/A, N=170, Not yet recruiting, NorthShore University HealthSystem | Initiation date: Dec 2023 --> Apr 2024

P1, N=3, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024

P1, N=26, Active, not recruiting, M.D. Anderson Cancer Center | N=48 --> 26

P1/2, N=14, Active, not recruiting, Avenge Bio, Inc | Recruiting --> Active, not recruiting | N=44 --> 14

A score based on total tumor volume, lesion count, the presence of peritoneal carcinomatosis, and age can guide MSI-H mCRC treatment decisions, allowing oncologists to identify suitable candidates for mono and combo ICI therapies.

P=N/A, N=166, Completed, CHU de Reims

P1/2, N=612, Recruiting, Regeneron Pharmaceuticals | N=326 --> 612 | Trial primary completion date: Jan 2027 --> Apr 2027

Our results suggest the TGFβ pathway as a crucial player in the development of brain metastases in primary CRC. In some types of colorectal cancer, downregulation of the TGFβ pathway might hinder primary colorectal cancer to metastasize to the nervous system. While the paradoxical functioning of the TGFβ pathway is still not fully understood, these shed light on yet another clinical implication of this complex pathway.

More importantly, CAR-NK cells combined with immune checkpoint inhibitors, anti-PD-L1, could synergistically enhance the antitumor efficacy of CLDN6-targeted CAR-NK cells. These results indicate that CLDN6-CAR NK cells possess strong antitumor activity and represent a promising immunotherapeutic modality for ovarian cancer.